Blog

For decades, cancer drug development has focused on blocking proteins—inhibiting enzymes, antagonizing receptors, disrupting signaling pathways. Yet this approach leaves a vast landscape of disease-driving proteins untouched, particularly those without enzymatic activity or binding pockets suitable for traditional small molecules. Now, a fundamentally different strategy is reshaping oncology: instead of merely inhibiting proteins, we can eliminate them entirely through targeted protein degradation. Introduction The concept of targeted protein degradation (TPD) represents a paradigm shift in how we approach cancer therapy. Rather than occupying a protein's active site to block its function, …